Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer.
Safi S, Yamauchi Y, Stamova S, Rathinasamy A, Op den Winkel J, Jünger S, Bucur M, Umansky L, Warth A, Herpel E, Eichhorn M, Winter H, Hoffmann H, Beckhove P. Safi S, et al. Among authors: bucur m. Oncoimmunology. 2019 Oct 23;8(12):e1671762. doi: 10.1080/2162402X.2019.1671762. eCollection 2019. Oncoimmunology. 2019. PMID: 31741774 Free PMC article.
Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.
Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schnölzer M, Warnken U, Schmitz-Winnenthal H, Ahmadi R, Dyckhoff G, Bucur M, Jünger S, Schueler T, Lennerz V, Woelfel T, Unterberg A, Herold-Mende C. Beckhove P, et al. Among authors: bucur m. J Clin Invest. 2010 Jun;120(6):2230-42. doi: 10.1172/JCI37646. Epub 2010 May 10. J Clin Invest. 2010. PMID: 20458140 Free PMC article.
Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.
Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, Herpel E, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C. Rapp C, et al. Among authors: bucur m. Acta Neuropathol. 2017 Aug;134(2):297-316. doi: 10.1007/s00401-017-1702-1. Epub 2017 Mar 22. Acta Neuropathol. 2017. PMID: 28332095
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: bucur m. Oncoimmunology. 2015 Mar 16;4(4):e1001217. doi: 10.1080/2162402X.2014.1001217. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137397 Free PMC article.
Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial.
Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, Heil J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F. Domschke C, et al. Among authors: bucur m. Cancer Immunol Immunother. 2013 Jun;62(6):1053-60. doi: 10.1007/s00262-013-1414-x. Epub 2013 Apr 18. Cancer Immunol Immunother. 2013. PMID: 23595207 Free PMC article.
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: bucur m. Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018. Oncoimmunology. 2018. PMID: 29632710 Free PMC article.
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D. Haag GM, et al. Among authors: bucur m. Eur J Cancer. 2018 Feb;90:122-129. doi: 10.1016/j.ejca.2017.12.001. Epub 2018 Jan 5. Eur J Cancer. 2018. PMID: 29306769 Clinical Trial.
87 results